In mice of mixed genetic backgrounds, intraperitoneal Sumatriptan succinate dose-dependently reduced cold-evoked nocifensive behaviors compared with vehicle. Repeated daily Sumatriptan succinate administration in wild-type mice produced facial mechanical hypersensitivity that persisted during subsequent administration and resolved after cessation. Following optogenetic CSD induction, hind-paw and periorbital allodynia were alleviated to varying degrees in mice receiving Sumatriptan in the CSD + Suma group relative to the CSD + NS group. [1,2,3]
Sumatriptan reduced nocifensive behaviors in control mice
Animal study · Male and female mice of mixed genetic backgrounds [1]
In the noxious cold plate assay, sumatriptan reduced nocifensive behaviors in control animals. Sumatriptan (30–300 μg/kg, i.p.) dose-dependently reduced nocifensive behaviors in the cold plate (0°C) assay.
Conditions shared by the study groups
- Route
- intraperitoneal injection
- Treatment course
- 30 min before behavior assays
- Vehicle
- saline
- Sumatriptan succinate 30–300 μg/kg
- Model: Male and female mice of mixed genetic backgrounds
Methods and source locations
Compound reported in the paper: Sumatriptan succinate; Compound label in the paper: Sumatriptan
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Analgesic actions of sumatriptan are mediated through Htr1b expressed in somatosensory neurons (S87); STAR★Methods > Experimental model and study participant details (S149); STAR★Methods > Method details > Drug treatments (S169); STAR★Methods > Method details > Cold and hot plate (S254); Figure 2 legend (S382)
nocifensive behaviors: nocifensive behaviors; comparator: vehicle — Results > Analgesic actions of sumatriptan are mediated through Htr1b expressed in somatosensory neurons (S87); Figure 2 legend (S382)
Sumatriptan succinate 30–300 μg/kg · Results > Analgesic actions of sumatriptan are mediated through Htr1b expressed in somatosensory neurons (S87); STAR★Methods > Method details > Drug treatments (S169); STAR★Methods > Method details > Cold and hot plate (S254); Figure 2 legend (S382)
Sumatriptan induces facial mechanical hypersensitivity in mice
Animal study · male and female wild-type mice; wild-type (C57BL/6J) [2]
In male and female wild-type mice, daily intraperitoneal Sumatriptan succinate produced robust facial mechanical hypersensitivity. Hypersensitivity was maintained by subsequent administration and resolved after treatment cessation.
Conditions shared by the study groups
- Route
- intraperitoneal (i.p.) injections
- Treatment course
- once every day for 12 days
- Vehicle
- saline
- Sumatriptan succinate 0.6 mg/kg
- Model: male and female wild-type mice; wild-type (C57BL/6J)
Methods and source locations
Compound reported in the paper: Sumatriptan succinate; Compound label in the paper: Sumatriptan
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Mouse model of medication overuse headache (S19, S20); Materials and methods > Drug treatments (S29); Results > The endogenous CCL2-CCR2 signaling pathway is not required for repeated sumatriptan-induced behavioral sensitization (S104, S105, S106); Fig. 2 legend (S178)
withdrawal thresholds to mechanical stimuli on facial skin: withdrawal thresholds to mechanical stimuli on facial skin; comparator: day 1 baseline threshold within individual groups — Materials and methods > Mouse model of medication overuse headache (S20); Results > The endogenous CCL2-CCR2 signaling pathway is not required for repeated sumatriptan-induced behavioral sensitization (S105, S106)
Sumatriptan succinate 0.6 mg/kg · Materials and methods > Mouse model of medication overuse headache (S19); Results > The endogenous CCL2-CCR2 signaling pathway is not required for repeated sumatriptan-induced behavioral sensitization (S105, S106)
Sumatriptan alleviates allodynia following optogenetic CSD induction
Animal study · Male C57BL/6 J wild-type mice (8–12 weeks); optogenetic CSD induction; CSD + Suma (n = 8) [3]
In male wild-type mice undergoing optogenetic CSD induction, Sumatriptan was administered intraperitoneally immediately after a single light stimulus. Hind-paw and periorbital allodynia were alleviated to varying degrees in the CSD + Suma group relative to the CSD + NS group.
Conditions shared by the study groups
- Route
- intraperitoneal injection
- Treatment course
- immediately after a single light stimulus; hind-paw (2.5 h, left: p = 0.008, right: p = 0.028; Fig. 6A)
- Vehicle
- 0.9% normal saline
- Sumatriptan 2 mg/kg, 0.02 ml/g of body weight
- Model: Male C57BL/6 J wild-type mice (8–12 weeks); optogenetic CSD induction; CSD + Suma (n = 8)
Methods and source locations
Compound reported in the paper: Sumatriptan
The paper names Sumatriptan without stating the salt or form; not verified as the succinate form supplied as A10879. No dose conversion or lot validation.
Methods > Animals (S1); Methods > Virus injection (S10, S14); Methods > Fiber-optic implantation and optogenetic CSD induction (S19, S39); Results > Sumatriptan alleviates optogenetic-induced migraine-like pain and anxiety behaviors (S104, S106); Fig. 1 legend (S122); Fig. 6 legend (S151, S152, S154)
hind-paw (A) and periorbital (B) withdrawal thresholds: hind-paw (A) and periorbital (B) withdrawal thresholds; comparator: CSD + NS group — Results > Sumatriptan alleviates optogenetic-induced migraine-like pain and anxiety behaviors (S106); Fig. 6 legend (S152)
Sumatriptan 2 mg/kg, 0.02 ml/g of body weight · Methods > Fiber-optic implantation and optogenetic CSD induction (S39); Results > Sumatriptan alleviates optogenetic-induced migraine-like pain and anxiety behaviors (S104, S106)
